Status:
COMPLETED
Evaluation of Meningococcal C Vaccine Programmes in Canadian Children
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Conditions:
Meningococcal Sero-type C Infection
Eligibility:
All Genders
12-13 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to see which of the three current provincial Meningococcal C Conjugate vaccine schedules in Canada provide the longest lasting protection against Meningococcal C disease an...
Detailed Description
In 2002-2005, Canada introduced universal MenC programmes consisting of 1,2 or 3 infant doses. Most are one (12 mth) dose. High rates of serogroupC disease in 2000 and 2001 prompted some provinces to ...
Eligibility Criteria
Inclusion
- 12-13 mths of age
- over 34 weeks gestation
- healthy children
- having had all vaccinations of Meningococcal C vaccine per the recommended schedule for their respective province within a month of the recommended age - documented.
- Communication in English
Exclusion
- No contraindication to receiving 12 mth dose of MenC vaccine
- No other MenC vaccine or MenC disease
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
452 Patients enrolled
Trial Details
Trial ID
NCT00936962
Start Date
July 1 2009
End Date
June 1 2015
Last Update
July 15 2015
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Alberta Health Services (Alberta Children's Hospital)
Calgary, Alberta, Canada
2
Vaccine Evaluation Center (University of BC at Children's Hospital)
Vancouver, British Columbia, Canada
3
Canadian Centre for Vaccinology (Dalhousie/IWK,)
Halifax, Nova Scotia, Canada